recurrent marginal zone lymphoma
Showing 1 - 25 of 86
Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,
Completed
- Grade 3a Follicular Lymphoma
- +9 more
- Laboratory Biomarker Analysis
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 31, 2023
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in
Suspended
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +7 more
- Venetoclax
- +3 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023
Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission, Acute Leukemia in Remission Trial in Seattle (drug,
Terminated
- Acute Biphenotypic Leukemia
- +29 more
- Cyclophosphamide
- +7 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 4, 2023
Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, MALT Trial in Duarte (biological, procedure,
Active, not recruiting
- Adult Grade III Lymphomatoid Granulomatosis
- +23 more
- autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 4, 2023
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +13 more
- Polatuzumab Vedotin
- +3 more
-
Scottsdale, Arizona
- +11 more
Aug 23, 2022
Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL, Recurrent Follicular Lymphoma Trial in Seattle (Nivolumab)
Recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +17 more
- Nivolumab
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 16, 2022
Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent DLBCL Trial in Rochester (procedure, biological,
Active, not recruiting
- Aggressive Non-Hodgkin Lymphoma
- +9 more
- Cryosurgery
- +5 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Aug 9, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +20 more
- Chimeric Antigen Receptor T-Cell Therapy
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 11, 2022
MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Atlanta, Columbus (drug, biological,
Completed
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- +8 more
- PI3K inhibitor BKM120
- +3 more
-
Atlanta, Georgia
- +1 more
Jun 27, 2022
MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,
Active, not recruiting
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- +9 more
- BTK inhibitor PCI-32765
- +5 more
-
Columbus, OhioOhio State University Medical Center
Jun 27, 2022
Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,
Withdrawn
- Recurrent Follicular Lymphoma
- +8 more
- (no location specified)
Jun 2, 2022
Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent DLBCL Trial in Atlanta, Columbus (other, drug, biological)
Recruiting
- Grade 3a Follicular Lymphoma
- +14 more
- Laboratory Biomarker Analysis
- +2 more
-
Atlanta, Georgia
- +1 more
May 31, 2022
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, Grade 1 Follicular Lymphoma,
Active, not recruiting
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
- +11 more
- Lenalidomide
- +2 more
-
Atlanta, Georgia
- +1 more
Apr 18, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,
Suspended
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +23 more
- Lenalidomide
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Feb 23, 2022
Hematopoietic Cell Transplantation Recipient, Recurrent DLBCL, Recurrent Grade 1 Follicular Lymphoma Trial in Columbus
Active, not recruiting
- Hematopoietic Cell Transplantation Recipient
- +11 more
- Carmustine
- +5 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Sep 29, 2021
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Terminated
- Adult Grade III Lymphomatoid Granulomatosis
- +116 more
- brentuximab vedotin
- +2 more
-
Chicago, Illinois
- +2 more
Aug 30, 2021
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of
Active, not recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +22 more
- Ibrutinib
- +3 more
-
Scottsdale, Arizona
- +1 more
Aug 10, 2021
Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Burkitt Lymphoma
Completed
- Adult Grade III Lymphomatoid Granulomatosis
- +88 more
- bortezomib
- +2 more
-
Detroit, MichiganBarbara Ann Karmanos Cancer Institute
Apr 14, 2021
Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With
Active, not recruiting
- Adult Acute Lymphoblastic Leukemia in Remission
- +46 more
- Fludarabine
- +8 more
-
Philadelphia, PennsylvaniaThomas Jefferson University
Feb 10, 2021
Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Completed
- Hematopoietic/Lymphoid Cancer
- +135 more
- beclomethasone dipropionate
- +4 more
-
Hackensack, New Jersey
- +1 more
Feb 1, 2021
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in
Completed
- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- +35 more
- Akt inhibitor MK2206
- laboratory biomarker analysis
-
Houston, TexasM D Anderson Cancer Center
Oct 14, 2020
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid
Completed
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- +99 more
- alemtuzumab
- +6 more
-
Denver, Colorado
- +6 more
Jan 15, 2020
Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma Trial in
Completed
- Acute Undifferentiated Leukemia
- +63 more
- total-body irradiation
- +7 more
-
Seattle, Washington
- +1 more
Jan 17, 2020
Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic
Completed
- Acute Myeloid Leukemia/Transient Myeloproliferative Disorder
- +76 more
- fludarabine phosphate
- +6 more
-
Tucson, Arizona
- +10 more
Jan 17, 2020
Marginal Zone Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia Trial in Seattle (drug, other,
Terminated
- Marginal Zone Lymphoma
- +5 more
- Carfilzomib
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 8, 2020